1. Clinical Presentation {#sec1}
========================

A 14-year-old female presented to our hospital with complaint of abdominal pain. Physical examination was unremarkable. She had no bleeding symptoms. The patient\'s past medical history was significant for Klippel-Feil syndrome and hearing loss. Prior platelet counts had been within normal ranges. The clinical concerns of her current low platelet count included idiopathic thrombocytopenic purpura and bone marrow suppression by a viral illness.

2. Laboratory Tests and Findings of Peripheral Blood Smear {#sec2}
==========================================================

The platelet count obtained on sample collected in ethylenediaminetetraacetic acid (EDTA) anticoagulant was 80,000 mm^3^. Hemoglobin (Hgb) and WBC were normal. Upon examination of peripheral blood (PB) smear, clumping of platelets was observed. Repeat testing on a sample collected in sodium citrate showed similarly low platelet count and PB smear showed platelet clumps as well. A photomicrograph of her stained PB smear is provided in [Figure 1](#fig1){ref-type="fig"}.

EDTA-dependent pseudothrombocytopenia (EDTA-PTCP) was suspected and the clinician was advised to send a sample in a heparin tube. Repeat testing of the new sample presumed to be collected in heparin showed normal platelet count. The CBC data/platelet counts obtained over prior months of past follow-up care were reviewed; see [Table 1](#tab1){ref-type="table"}.

3. Discussion {#sec3}
=============

EDTA-dependent pseudothrombocytopenia (EDTA-PTCP) is a common laboratory phenomenon with estimated prevalence of 0.1%--2% in hospitalized patients \[[@B1], [@B2]\]. It is due to in vitro agglutination of platelets in the blood collection tube caused by IgM/IgG autoantibodies directed against epitopes on platelet surface glycoprotein (GP) IIb/IIIa. EDTA induces a conformational change in GPIIb/IIIa, exposing these epitopes and resulting in platelet agglutination \[[@B3]\]. The use of an alternate anticoagulant, such as citrate or heparin, may be helpful. However, up to 17% of patients with EDTA-PTCP also show this phenomenon with citrate \[[@B2], [@B3]\].

Bizzaro conducted a large study of EDTA-PTCP cases and found that 83% had antiplatelet antibodies. The phenomenon was not age-related or gender-related, nor was it associated with any particular pathology or use of specific drugs. It showed that EDTA-dependent PTCP is a phenomenon related to the presence of natural autoantibodies with antiplatelet activity and is not associated with any pathological significance \[[@B4]\].

It is important to differentiate EDTA-associated thrombocytopenia from that seen in type 2B von Willebrand disease (vWD type 2B). Kumar and colleagues reported a case of vWD type 2B in a child that was misconstrued as EDTA-PTCP \[[@B3]\]. The patient presented with extensive bruising. CBC showed thrombocytopenia, baseline coagulation profile was normal, and PB smear showed platelet clumping. Due to the severity of bruising, child abuse was suspected as thrombocytopenia was initially misconstrued as being caused by EDTA-related platelet clumping. Further coagulation work-up revealed low von Willebrand factor antigen and ristocetin cofactor activity, and molecular testing confirmed vWD type 2B \[[@B3]\]. The latter is an in vivo consumption of platelet, which results in true thrombocytopenia. Additionally, due to the consumptive nature and compensatory regenerative activity in megakaryocytic cell line, causing a platelet "left shift," the mean platelet volume (MPV) is increased in vWD type 2B. This morphologic observation may help further separate the two conditions presumptively upon examination of PB smear; refer to [Figure 2](#fig2){ref-type="fig"} for morphologic comparison and [Table 2](#tab2){ref-type="table"} for comparative features.

Other possible preanalytical factors to consider upon investigating platelet clumps include the collection method, that is, capillary venous or line draws. Capillary collections are prone to clotting and formation of platelet clumps. Viral infection, drugs, and medications, especially chemotherapeutic agents, are all possible inducers of platelet clumping \[[@B5], [@B6]\].

Clumping can also be due to a combination of more than one of the above factors, and it is possible that a transient viral infection was a confounding cause in our patient (note the atypical lymphocyte suggestive of a viral infection seen in [Figure 1](#fig1){ref-type="fig"} and the CBC results listed in [Table 1](#tab1){ref-type="table"} showing the fluctuation in WBC, RBC, and Hgb levels coinciding with episodes of clumping and returning to normal levels along with the platelet count).

4. Recommendations {#sec4}
==================

From a practical laboratory point of view, investigation of platelet clumping may include the following steps until a nonclumping smear is obtained, noting that Steps [3](#step3){ref-type="statement"} and [4](#step4){ref-type="statement"} are reserved for the rare instances, where Steps [1](#step1){ref-type="statement"} and [2](#step2){ref-type="statement"} do not resolve the platelet clumping.

Step 1 .Verify method of blood draw (e.g., finger stick versus venipuncture versus line draw) and exclude collection method related clotting.

Step 2 .Test a blood sample collected in sodium citrate.

If clumping persists, continue to [Step 3](#step3){ref-type="statement"}.

Step 3 .Test a sample collected in heparin. If [Step 3](#step3){ref-type="statement"} is not possible, proceed to [Step 4](#step4){ref-type="statement"}.

Step 4 .Obtain a sample in ammonium oxalate, and count platelets utilizing a hemocytometer grid, if available, as per described methods \[[@B4]\].

Modern hematology analyzers "flag" platelet clumps, and this should prompt manual verification by examination of a stained PB smear. Reporting platelet counts on samples that show platelet clumps can be a challenge. A recommended approach is not to give a platelet result value for a sample with clumps if the instrument\'s count is below the lower limits of normal, report the clumping, and recommend one of the steps described above. If the instruments\' platelet count of a sample is within or above normal range, a count may be given with an added comment noting the presence of platelet clumps and suggesting that the true count is likely higher than reported.
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![Peripheral blood smear (100x oil).](CRIHEM2016-3036476.001){#fig1}

![Platelets size and morphology of EDTA-associated clumps in (a) and (b); vWD type 2B-associated clumps in (c) and (d). Note the larger and more variable in size platelets in the latter (all photomicrographs are taken using the same 100x oil lens).](CRIHEM2016-3036476.002){#fig2}

###### 

Patient\'s CBC and platelet counts over the period of care and follow-up.

  -------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Chronology of follow-up testing   Platelet count, ×10^3^/uL           WBC\      RBC\      Hgb\   Collection tube additive   Collection method   Collection volume
                                                                        K/cu mm   M/cu mm   g/dL                                                  
  --------------------------------- ----------------------------------- --------- --------- ------ -------------------------- ------------------- -------------------
  Follow-up                                                                                                                                        

   Day 1                            165                                 8.8       5.02      15.0   EDTA                       Unknown             Unknown

   Day 110                          106                                 8.0       5.05      14.6   EDTA                       Venipuncture        3 mL

   Day 117                          87                                  8.2       4.78      14.1   EDTA                       Venipuncture        3 mL

   Day 124                          88                                  8.0       5.00      14.7   EDTA                       Venipuncture        3 mL

   Day 155                          Unable to report, platelet clumps   6.6       4.75      14.1   EDTA                       Venipuncture        3 mL

   Day 156                          85                                  5.0       4.65      13.6   EDTA                       Venipuncture        3 mL

   Day 188                          Unable to report, platelet clumps   4.6       4.70      13.6   EDTA                       Venipuncture        3 mL

   Day 202^*∗*^                     Unable to report, platelet clumps   7.7       4.89      14.4   Na citrate                 Venipuncture        2.7 mL

  EDTA                              3 mL                                                                                                          

   Day 216                          184                                 8.4       4.88      14.3   Heparin^*∗∗*^              Venipuncture        3 mL
  -------------------------------------------------------------------------------------------------------------------------------------------------------------------

^*∗*^Encounter described in this case report.

^*∗∗*^Sample collection in a heparin tube was noted in records but could not be verified.

###### 

Comparison between EDTA-associated and vWD type 2B-associated platelet clumping.

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Distinguishable features                       EDTA-associated                                            vWD type 2B-associated
  ---------------------------------------------- ---------------------------------------------------------- ------------------------------------------------------------------------
  Clumping                                       Due to in vitro process                                    Due to in vivo process

  Bleeding tendency                              None                                                       Characteristic

  MPV                                            Normal                                                     Increased due to left shift

  Further work-up to confirm platelet clumping   Testing citrate or heparin anticoagulated sample, others   \(1\) Platelet aggregation studies using low ristocetin concentration\
                                                                                                            (2) Molecular testing (Exon 28 sequencing)
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
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